MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT

A subset of AML patients are unfit for 7+3 induction at the time of diagnosis. Present case highlights the use of azacitidine and venetoclax in a patient with intermediate risk AML with WT-1 mutation,deemed unfit for intensive induction in view of poor general condition and comorbid illness. After v...

Descripción completa

Detalles Bibliográficos
Autores principales: Shukla, Deepak Kumar, Katewa, Satyendra, Porwal, Ravikant, Dara, Ravi, Sharma, Lalit, Sharma, Rahul, Arora, Aadesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436161/
https://www.ncbi.nlm.nih.gov/pubmed/34540583
http://dx.doi.org/10.1016/j.lrr.2021.100267
_version_ 1783751947326586880
author Shukla, Deepak Kumar
Katewa, Satyendra
Porwal, Ravikant
Dara, Ravi
Sharma, Lalit
Sharma, Rahul
Arora, Aadesh
author_facet Shukla, Deepak Kumar
Katewa, Satyendra
Porwal, Ravikant
Dara, Ravi
Sharma, Lalit
Sharma, Rahul
Arora, Aadesh
author_sort Shukla, Deepak Kumar
collection PubMed
description A subset of AML patients are unfit for 7+3 induction at the time of diagnosis. Present case highlights the use of azacitidine and venetoclax in a patient with intermediate risk AML with WT-1 mutation,deemed unfit for intensive induction in view of poor general condition and comorbid illness. After venetoclax and azacitidine patient was negative for measurable residual disease but developed cerebellar toxicity after high dose cytarabine. He underwent successful matched sibling allogeneic stem cell transplant and is presently on routine follow up. This case report suggest possible role of this combination even in young patients unfit for intensive induction.
format Online
Article
Text
id pubmed-8436161
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84361612021-09-17 MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT Shukla, Deepak Kumar Katewa, Satyendra Porwal, Ravikant Dara, Ravi Sharma, Lalit Sharma, Rahul Arora, Aadesh Leuk Res Rep Article A subset of AML patients are unfit for 7+3 induction at the time of diagnosis. Present case highlights the use of azacitidine and venetoclax in a patient with intermediate risk AML with WT-1 mutation,deemed unfit for intensive induction in view of poor general condition and comorbid illness. After venetoclax and azacitidine patient was negative for measurable residual disease but developed cerebellar toxicity after high dose cytarabine. He underwent successful matched sibling allogeneic stem cell transplant and is presently on routine follow up. This case report suggest possible role of this combination even in young patients unfit for intensive induction. Elsevier 2021-09-06 /pmc/articles/PMC8436161/ /pubmed/34540583 http://dx.doi.org/10.1016/j.lrr.2021.100267 Text en © 2021 The Author(s). Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Shukla, Deepak Kumar
Katewa, Satyendra
Porwal, Ravikant
Dara, Ravi
Sharma, Lalit
Sharma, Rahul
Arora, Aadesh
MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
title MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
title_full MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
title_fullStr MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
title_full_unstemmed MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
title_short MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
title_sort mrd negative cr after azacitidine and venetoclax in a young patient with aml, unfit for intensive induction followed by asct
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436161/
https://www.ncbi.nlm.nih.gov/pubmed/34540583
http://dx.doi.org/10.1016/j.lrr.2021.100267
work_keys_str_mv AT shukladeepakkumar mrdnegativecrafterazacitidineandvenetoclaxinayoungpatientwithamlunfitforintensiveinductionfollowedbyasct
AT katewasatyendra mrdnegativecrafterazacitidineandvenetoclaxinayoungpatientwithamlunfitforintensiveinductionfollowedbyasct
AT porwalravikant mrdnegativecrafterazacitidineandvenetoclaxinayoungpatientwithamlunfitforintensiveinductionfollowedbyasct
AT dararavi mrdnegativecrafterazacitidineandvenetoclaxinayoungpatientwithamlunfitforintensiveinductionfollowedbyasct
AT sharmalalit mrdnegativecrafterazacitidineandvenetoclaxinayoungpatientwithamlunfitforintensiveinductionfollowedbyasct
AT sharmarahul mrdnegativecrafterazacitidineandvenetoclaxinayoungpatientwithamlunfitforintensiveinductionfollowedbyasct
AT aroraaadesh mrdnegativecrafterazacitidineandvenetoclaxinayoungpatientwithamlunfitforintensiveinductionfollowedbyasct

Ejemplares similares